FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不 ...

FF305 | 2. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年3月31日 | 39,141,840 | | | 0 | | 39,141,840 | | 1). | 其他 (請註明) | | | % | | | | | 見B部 | | | | | | | | | 變動日期 | 2025年4月7日 | | | | | | | | 於下列日期結束時的結存 (註5及6) | 2025年4 ...

FF301 第 1 頁 共 12 頁 v 1.1.1 備註： | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | | A股（上海證券交易所科創板，股份代號：688366） | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 194,051,855 | RMB | | 1 RMB | | 194,051,855 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 194,051,855 | RMB | | 1 RMB | | 194,051,855 | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

Investment Rating - The report maintains a "Recommended" investment rating for the optional consumption industry [6] Core Insights - The report highlights a focus on performance realization and improvement in market conditions as annual reports are being disclosed [2] - The optional consumption sector has shown varied performance, with specific segments like tourism benefiting from the Qingming holiday, while others like education and professional chains have seen declines [12][14] Summary by Sections Market Performance - For the week of March 24-28, 2025, the performance of the Shenwan retail, social services, and beauty care sectors was -2.05%, -1.96%, and -1.64% respectively, ranking them 23rd, 20th, and 16th among 31 primary industries [12][14] - The Shanghai Composite Index decreased by 0.40%, while the Shenzhen Component Index fell by 0.75%, and the CSI 300 Index remained flat at +0.01% [12] Key Events and Announcements - Beauty Care: - Juzhibio reported a revenue of 5.539 billion yuan in 2024, up 57.2% year-on-year, with a net profit of 2.152 billion yuan, a 46.5% increase [21] - Kefu Mei achieved a revenue of 4.54 billion yuan, growing 62.9% year-on-year [21] - Maogeping's revenue reached 3.885 billion yuan, a 34.6% increase, with a gross margin of 84.4% [21] - Retail: - Pop Mart's revenue surpassed 10 billion yuan for the first time in 2024, with a year-on-year growth of 106.9% [20] - Chinagoods platform registered over 4.8 million buyers, and Yiwu International Trade City saw a 12.15% increase in daily foot traffic [22] - Social Services: - Meixue Ice City reported a revenue of 24.829 billion yuan, up 22.3% year-on-year, with a net profit of 4.454 billion yuan, a 39.8% increase [24] - Bawang Tea Ji submitted an IPO application, reporting a GMV of 29.5 billion yuan and revenue of 12.405 billion yuan in 2024 [25]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 中國上海，2025年4月1日 於本公告日 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-015 上海昊海生物科技股份有限公司 书》（公告编号：2024-042）。 公司 A 股 2024 年半年度权益分派实施完毕后，本次以集中竞价交易方式回购 公司 A 股股份价格上限由不超过 89.71 元/股（含），调整为不超过 89.31 元/股（含）。 具体内容详见公司于 2024 年 10 月 11 日在上海证券交易所网站（www.sse.com.cn） 披露的《上海昊海生物科技股份有限公司关于 2024 年半年度权益分派实施后调整 回购 A 股股份价格上限的公告》（公告编号：2024-056）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应当在每个月的前 3 个交易日 内公告截至上月末的回购进展情况。现将公司回购 A 股股份进展情况公告如下： 2025 年 3 月，公司通过集中竞价交易方式累计回购公司 A 股股份 164,190 股， 占公司总股本 233,193,695 股的比例为 0.07%，最高成交价为 61.20 元/股，最低成 交 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company has shown steady growth in hyaluronic acid products, which is driving stable growth in the medical aesthetics sector. The newly launched "Hai Mei Yue Bai" is expected to become a significant revenue contributor [2]. - The execution of centralized procurement has led to a decrease in terminal prices for artificial lenses, but the rapid growth of mid-to-high-end products is continuously optimizing the product structure [2]. - The company is making progress in the research and development of innovative ophthalmic products, enriching its product line [2][3]. Financial Performance - In 2024, the company achieved operating revenue of 2.698 billion yuan, a year-on-year increase of 1.64%. The net profit attributable to the parent company was 420 million yuan, up 1.04% year-on-year [1]. - The revenue from the medical aesthetics and wound care business reached 1.195 billion yuan, representing a year-on-year growth of 13.08%, accounting for 44.38% of total revenue [2]. - The revenue from hyaluronic acid products was 742 million yuan, with a year-on-year growth of 23.23% [2]. Product Segmentation - **Hyaluronic Acid**: Revenue of 742 million yuan, with the third-generation product "Hai Mei" maintaining rapid growth and the fourth-generation product "Hai Mei Yue Bai" starting to contribute to revenue [2]. - **Human Epidermal Growth Factor**: Revenue of 189 million yuan, a year-on-year increase of 10.69% [2]. - **Radiofrequency and Laser Equipment**: Revenue of 264 million yuan, a decline of 6.97%, although certain products showed significant growth [2]. - **Ophthalmic Business**: Revenue of 858 million yuan, a year-on-year decline of 7.60%, with cataract business revenue at 421 million yuan, down 15.33% [3]. Profitability and Margins - The company's gross margin for 2024 was 69.88%, a slight decrease of 0.62 percentage points year-on-year, primarily due to price declines in artificial lenses and viscoelastic agents [4]. - The proportion of high-margin hyaluronic acid products is increasing, which is expected to enhance overall profitability [4]. Future Projections - Revenue forecasts for 2025-2027 are 3.125 billion, 3.633 billion, and 4.237 billion yuan, with year-on-year growth rates of 15.8%, 16.3%, and 16.6% respectively [4]. - Net profit attributable to the parent company is projected to be 507 million, 620 million, and 759 million yuan for the same period, with growth rates of 20.6%, 22.3%, and 22.5% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company has shown steady growth in hyaluronic acid products, which is driving stable growth in the medical aesthetics sector. The newly launched "Hai Mei Yue Bai" is expected to become a significant revenue contributor [2]. - The company is optimizing its product structure in the ophthalmology segment, with high-end artificial lenses continuing to gain market share despite price pressures from centralized procurement [3]. - The overall revenue for 2024 is reported at 2.698 billion yuan, a year-on-year increase of 1.64%, while the net profit attributable to the parent company is 420 million yuan, up 1.04% year-on-year [1]. Summary by Sections Revenue and Profitability - In 2024, the company achieved operating revenue of 2.698 billion yuan, with a net profit of 420 million yuan. The revenue for Q4 2024 was 623 million yuan, down 7.35% year-on-year [1]. - The gross margin for 2024 was 69.88%, slightly down by 0.62 percentage points, primarily due to price declines in artificial lenses and viscoelastic agents [4]. Product Performance - The medical aesthetics and wound care business generated revenue of 1.195 billion yuan, a year-on-year increase of 13.08%, accounting for 44.38% of total revenue [2]. - Revenue from hyaluronic acid products reached 742 million yuan, growing by 23.23%, with the third-generation product "Hai Mei" maintaining rapid growth [2]. - The ophthalmology segment reported revenue of 858 million yuan, a decline of 7.60%, with cataract business revenue at 421 million yuan, down 15.33% [3]. Research and Development - The company is making progress in R&D, with several innovative products entering registration phases, including smart cross-linked collagen and injectable hydroxyapatite microspheres [2][3]. - The product line in the ophthalmology sector is continuously expanding, with new products like multi-focal and tri-focal lenses showing promising development [3]. Financial Forecast - The company is projected to achieve revenues of 3.125 billion yuan, 3.633 billion yuan, and 4.237 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 507 million yuan, 620 million yuan, and 759 million yuan [4][5].

Core Points - The company announces the departure of core technical personnel, Mr. Gan Renbao, due to age, and confirms that this will not impact the company's technology development or operations [1][5] - Mr. Gan has not participated in any ongoing projects and has completed the handover of his responsibilities [1][3] - The company has a stable research and development (R&D) team, with the number of R&D personnel remaining consistent over the years [5][7] Departure Details - Mr. Gan Renbao, born in 1939, has a background in biochemistry and cell biology, and has been with the company since July 2010 [1] - He has contributed to two patented inventions during his tenure, which are owned by the company, and there are no disputes regarding intellectual property rights [3][5] - As of the announcement date, Mr. Gan does not hold any shares in the company [2] Impact on the Company - The departure of Mr. Gan will not adversely affect the company's core technologies or competitive capabilities, as the existing R&D team is well-structured and capable [5][7] - The company has a total of 344, 366, and 350 R&D personnel projected for the end of 2022, 2023, and 2024 respectively, indicating a stable workforce [5] - The company emphasizes its commitment to R&D and has established a comprehensive project management system to ensure continuous innovation [7] Confidentiality Agreement - A confidentiality agreement is in place with Mr. Gan, ensuring that he will not disclose any company secrets post-departure [4] - There have been no indications of Mr. Gan joining a competitor or violating the confidentiality terms [4]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於公司核心技術人員離職的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年3月28日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号 ...